{"id":"https://openalex.org/W34571862","doi":"https://doi.org/10.1200/jco.2010.28.15_suppl.2055","title":"Phase II trial of bevacizumab plus erlotinib for patients with recurrent malignant gliomas: Final results.","display_name":"Phase II trial of bevacizumab plus erlotinib for patients with recurrent malignant gliomas: Final results.","publication_year":2010,"publication_date":"2010-05-20","ids":{"openalex":"https://openalex.org/W34571862","doi":"https://doi.org/10.1200/jco.2010.28.15_suppl.2055","mag":"34571862"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2010.28.15_suppl.2055","doi":"https://doi.org/10.1200/jco.2010.28.15_suppl.2055","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2010.28.15_suppl.2055","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","doyens","jufo-3","ki-jl-3","medline","norway-2"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5085537336","display_name":"Sith Sathornsumetee","orcid":"https://orcid.org/0000-0003-1350-0672","observed_orcids":["https://orcid.org/0000-0003-1350-0672"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"S. Sathornsumetee","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002201007","display_name":"Annick Desjardins","orcid":"https://orcid.org/0000-0003-3869-8283","observed_orcids":["https://orcid.org/0000-0003-3869-8283"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"A. Desjardins","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014505996","display_name":"James J. Vredenburgh","orcid":"https://orcid.org/0000-0002-2935-6057","observed_orcids":["https://orcid.org/0000-0002-2935-6057"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"J. J. Vredenburgh","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5058437089","display_name":"R E McLendon","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"R. E. McLendon","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5020491326","display_name":"Jennifer E. Marcello","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"J. Marcello","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011590188","display_name":"James E. Herndon","orcid":"https://orcid.org/0000-0001-7998-3588","observed_orcids":["https://orcid.org/0000-0001-7998-3588"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"J. E. Herndon","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5058264030","display_name":"Julie A. Norfleet","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"J. Norfleet","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043001715","display_name":"Sridharan Gururangan","orcid":"https://orcid.org/0000-0003-0311-7127","observed_orcids":["https://orcid.org/0000-0003-0311-7127"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"S. Gururangan","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109896919","display_name":"H. S. Friedman","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"H. S. Friedman","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5059965175","display_name":"David A. Reardon","orcid":"https://orcid.org/0000-0001-6674-0157","observed_orcids":["https://orcid.org/0000-0001-6674-0157"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"D. A. Reardon","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":4,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"28","issue":"15_suppl","first_page":"2055","last_page":"2055"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10129","display_name":"Glioma Diagnosis and Treatment","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10129","display_name":"Glioma Diagnosis and Treatment","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10422","display_name":"Angiogenesis and VEGF in Cancer","score":0.0006000000284984708,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10550","display_name":"Ovarian cancer diagnosis and treatment","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2743","display_name":"Reproductive Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/bevacizumab","display_name":"bevacizumab","score":0.9629999995231628},{"id":"https://openalex.org/keywords/erlotinib","display_name":"erlotinib","score":1.0},{"id":"https://openalex.org/keywords/recurrent-malignant-glioma","display_name":"recurrent malignant glioma","score":0.984000027179718},{"id":"https://openalex.org/keywords/glioblastoma","display_name":"glioblastoma","score":0.9610000252723694},{"id":"https://openalex.org/keywords/anaplastic-glioma","display_name":"anaplastic glioma","score":0.9980000257492065},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.8859999775886536},{"id":"https://openalex.org/keywords/enzyme-inducing-anticonvulsants","display_name":"enzyme-inducing anticonvulsants","score":0.8679999709129333},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.7409999966621399},{"id":"https://openalex.org/keywords/vegfr2","display_name":"VEGFR2","score":0.9980000257492065},{"id":"https://openalex.org/keywords/drug-toxicity","display_name":"drug toxicity","score":0.4350000023841858},{"id":"https://openalex.org/keywords/skin-rash","display_name":"rash","score":0.6790000200271606},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.5139999985694885},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.5149999856948853},{"id":"https://openalex.org/keywords/angiogenesis-inhibition","display_name":"angiogenesis inhibition","score":0.5609999895095825},{"id":"https://openalex.org/keywords/egfr-tyrosine-kinase-inhibitors","display_name":"EGFR tyrosine kinase inhibitors","score":0.8579999804496765}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9660735130310059},{"id":"https://openalex.org/C2777802072","wikidata":"https://www.wikidata.org/wiki/Q413299","display_name":"Bevacizumab","level":3,"score":0.7894712090492249},{"id":"https://openalex.org/C2778087573","wikidata":"https://www.wikidata.org/wiki/Q418369","display_name":"Erlotinib","level":4,"score":0.7644544839859009},{"id":"https://openalex.org/C2778570526","wikidata":"https://www.wikidata.org/wiki/Q653197","display_name":"Rash","level":2,"score":0.6603783965110779},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5397788286209106},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.5315496921539307},{"id":"https://openalex.org/C2778227246","wikidata":"https://www.wikidata.org/wiki/Q1365309","display_name":"Glioma","level":2,"score":0.4772738814353943},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.4636387228965759},{"id":"https://openalex.org/C2778496288","wikidata":"https://www.wikidata.org/wiki/Q6931269","display_name":"Mucositis","level":3,"score":0.4596090316772461},{"id":"https://openalex.org/C2778456384","wikidata":"https://www.wikidata.org/wiki/Q1508510","display_name":"Perforation","level":3,"score":0.4373123347759247},{"id":"https://openalex.org/C2781413609","wikidata":"https://www.wikidata.org/wiki/Q7308373","display_name":"Regimen","level":2,"score":0.42318612337112427},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.38394805788993835},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.21289879083633423},{"id":"https://openalex.org/C2779438470","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"Epidermal growth factor receptor","level":3,"score":0.1915823221206665},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.0},{"id":"https://openalex.org/C2778527123","wikidata":"https://www.wikidata.org/wiki/Q11750728","display_name":"Punching","level":2,"score":0.0},{"id":"https://openalex.org/C192562407","wikidata":"https://www.wikidata.org/wiki/Q228736","display_name":"Materials science","level":0,"score":0.0},{"id":"https://openalex.org/C191897082","wikidata":"https://www.wikidata.org/wiki/Q11467","display_name":"Metallurgy","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2010.28.15_suppl.2055","doi":"https://doi.org/10.1200/jco.2010.28.15_suppl.2055","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2010.28.15_suppl.2055","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","doyens","jufo-3","ki-jl-3","medline","norway-2"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"sustainable_development_goals_aurora":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.8399999737739563}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W1991907323","https://openalex.org/W3159514559","https://openalex.org/W2142374454","https://openalex.org/W2466738390","https://openalex.org/W2376769477","https://openalex.org/W2804337541","https://openalex.org/W2105984177","https://openalex.org/W2158106887","https://openalex.org/W43664894","https://openalex.org/W2736712994"],"abstract_inverted_index":{"2055":[0],"Background:":[1],"Bevacizumab":[2,26,280],"has":[3],"antiglioma":[4],"activity":[5,19],"as":[6],"single":[7,227],"agent":[8],"and":[9,66,87,159,172,177,185,206,212,225,251,265],"in":[10,20,34,49,247,257,267,276,286],"combination":[11],"with":[12,31,51,126,254,272,305],"cytotoxic":[13],"therapy.":[14],"Erlotinib":[15,72],"may":[16],"exhibit":[17],"antitumor":[18],"some":[21],"malignant":[22],"glioma":[23],"(MG)":[24],"patients.":[25,259,278,289],"plus":[27,47,281],"erlotinib":[28,48,202,282,294],"was":[29,58,73,169,245,252,283],"associated":[30,253,271],"clinical":[32],"benefit":[33,256],"several":[35],"solid":[36],"tumors.":[37],"Here":[38],"we":[39],"reported":[40],"the":[41,291],"final":[42],"study":[43],"results":[44],"of":[45,99,201,249,262,293],"bevacizumab":[46,100,296],"patients":[50,81,91,95,147,184,189,228,250],"recurrent":[52,287],"MG.":[53],"Methods:":[54],"The":[55,152,165],"primary":[56],"endpoint":[57],"6-month":[59],"progression-free":[60,300],"survival":[61,168,255,274],"(PFS-6).":[62],"Radiographic":[63],"response,":[64],"pharmacokinetics":[65],"correlative":[67],"biomarkers":[68],"were":[69,142,148,155,214,223,270],"secondary":[70],"endpoints.":[71],"orally":[74],"administered":[75],"daily":[76],"at":[77,191],"200":[78],"mg/day":[79,89],"for":[80,90,133,150,157,161,175],"not":[82,298],"on":[83,92,139],"enzyme-inducing":[84],"anticonvulsants":[85],"(EIAC)":[86],"500":[88],"EIAC.":[93],"All":[94],"received":[96],"10":[97],"mg/kg":[98],"intravenously":[101],"every":[102],"two":[103],"weeks.":[104],"Key":[105],"eligibility":[106],"criteria":[107],"included:":[108],"age":[109],"\u2265":[110,114],"18":[111],"years;":[112],"KPS":[113],"60;":[115],">":[116,128],"4":[117],"weeks":[118,171,174],"from":[119],"prior":[120,130],"surgery,":[121],"XRT":[122],"or":[123,136,238,312,316],"chemotherapy.":[124],"Patients":[125],"either":[127,231],"3":[129,243],"progressions,":[131],"requirement":[132],"therapeutic":[134],"anti-coagulation":[135],"acute":[137],"hemorrhage":[138],"pre-treatment":[140],"imaging":[141],"excluded.":[143],"Results:":[144],"Fifty-six":[145],"(98%)":[146],"assessable":[149],"outcome.":[151],"PFS-6":[153],"rates":[154],"29%":[156],"GBM":[158,176,183,258,277],"44%":[160],"anaplastic":[162],"gliomas":[163],"(AG).":[164],"median":[166],"overall":[167],"45":[170],"76":[173],"AG":[178,188],"patients,":[179],"respectively.":[180],"Twelve":[181],"(50%)":[182],"ten":[186],"(31%)":[187],"experienced":[190],"least":[192],"partial":[193],"radiographic":[194],"responses.":[195],"Pharmacokinetic":[196],"analyses":[197],"showed":[198],"no":[199],"difference":[200],"exposure":[203],"between":[204],"EIAC":[205],"non-EIAC":[207],"groups.":[208],"Rash,":[209],"mucositis,":[210],"diarrhea":[211],"fatigue":[213],"common":[215],"but":[216],"mostly":[217],"grade":[218],"1-2.":[219],"Serious":[220],"side":[221],"effects":[222],"rare":[224],"included":[226],"who":[229],"developed":[230],"intestinal":[232],"perforation,":[233],"arterial":[234],"thrombosis,":[235],"pulmonary":[236],"embolism":[237],"nasal":[239],"septal":[240],"perforation.":[241],"Grade":[242],"rash":[244],"found":[246],"39%":[248],"High":[260],"levels":[261],"HIF-2":[263],"alpha":[264],"VEGFR-2":[266],"archival":[268],"tumors":[269],"poor":[273],"outcome":[275],"Conclusions:":[279],"adequately":[284],"tolerated":[285],"MG":[288],"However,":[290],"addition":[292],"to":[295],"did":[297],"improve":[299],"survival,":[301],"when":[302],"historically":[303],"compared":[304],"other":[306],"bevacizumab-containing":[307],"regimens.":[308],"Author":[309],"Disclosure":[310],"Employment":[311],"Leadership":[313],"Position":[314],"Consultant":[315],"Advisory":[317],"Role":[318],"Stock":[319],"Ownership":[320],"Honoraria":[321],"Research":[322],"Funding":[323],"Expert":[324],"Testimony":[325],"Other":[326],"Remuneration":[327],"Genentech":[328,329,330]},"counts_by_year":[{"year":2022,"cited_by_count":1},{"year":2012,"cited_by_count":1}],"updated_date":"2026-09-22T06:50:58.402377","created_date":"2025-10-10T00:00:00"}